Evidence map›Paper›PMID 36444554›Full record

ArticleCancer2023

Risk of subsequent primary lymphoma in a cohort of 69,460 five-year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study.

Isabelle M Dudley, Ceren Sunguc, Emma J Heymer, David L Winter, Jop C Teepen, Fabiën N Belle, Edit Bárdi, Francesca Bagnasco, Thorgerdur Gudmundsdottir, Roderick Skinner and 29 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03297034 (Swiss Childhood Cancer Survivor Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03297034 recruitingnot on this map

Swiss Childhood Cancer Survivor Study (SCCSS)

Typeobservational_patient_registrySponsorUniversity of BernRan2007 to 2050Enrolled4,136ConditionsChildhood Cancer
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Cohort Profile Update: The Swiss Childhood Cancer Survivor Cohort.International journal of epidemiology · 2026
    Article
  2. Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Isabelle M DudleyCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Ceren SungucCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-7831-960X
Emma J HeymerCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-5115-0293
David L WinterCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-1597-4081
Jop C TeepenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-2647-2677
Fabiën N BelleChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0037-4817
Edit BárdiSt Anna Children's Hospital, Vienna, Austria.ORCID 0000-0001-7424-6255
Francesca BagnascoScientific Directorate, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0003-1601-9518
Thorgerdur GudmundsdottirDanish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.ORCID 0000-0001-6396-1018
Roderick SkinnerGreat North Children's Hospital, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK.ORCID 0000-0002-1162-675X
Gisela MichelDepartment of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID 0000-0002-9589-0928
Julianne ByrneBoyne Research Institute, Bettystown, Co Meath, Ireland.ORCID 0000-0002-1070-3004
Hilde ØfstaasDivision of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Momcilo JankovicPediatric Clinic, University of Milano-Bicocca, Hospital San Gerardo, Monza, Italy.ORCID 0000-0001-9773-0576
Maja Česen MazićUniversity Children's Hospital Ljubljana, University Medical Center Ljubljana, Ljubljana, Slovenia.ORCID 0000-0003-2434-8960
Luzius MaderChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-5613-4356
Jaqueline LoonenDepartment of Hematology, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-9963-8367
Stanislaw GarwiczDepartment of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden.
Thomas WiebeDepartment of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden.ORCID 0000-0002-7567-9076
Daniela AlessiChildhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0002-3746-3346
Rodrigue S AllodjiRadiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France.ORCID 0000-0002-1895-8415
Nadia HaddyRadiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France.ORCID 0000-0001-9316-8280
Desiree GrabowGerman Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-4853-3303
Peter KaatschGerman Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-8565-0832
Melanie KaiserGerman Childhood Cancer Registry, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics, Johannes-Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0002-3362-2530
Milena M MauleChildhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0003-2142-1288
Zsuzsanna JakabHungarian Childhood Cancer Registry, Second Department of Pediatrics, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-5410-1187
Maria Winther GunnesDivision of Pediatric and Adolescent Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.ORCID 0000-0003-2514-0547
Monica TerenzianiPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-7080-6718
Lorna Zadravec ZaletelDivision of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.ORCID 0000-0002-4423-0276
Claudia E KuehniChildhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-8957-2002
Riccardo HauptDiagnosis, Observation, Prevention After Oncologic Treatment (DOPO) Clinic, Division of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0003-0571-8460
Florent de VathaireRadiation Epidemiology Team, Center for Research in Epidemiology and Population Health, National Institute of Health and Medical Research Unit 1018, University Paris Saclay, Gustave Roussy, Villejuif, France.ORCID 0000-0002-8374-9281
Leontien C KremerPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0001-7422-3248
Päivi M LähteenmäkiDepartment of Pediatrics and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland.ORCID 0000-0002-5500-9606
Jeanette F WintherDanish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.ORCID 0000-0002-3440-5108
Lars HjorthDepartment of Clinical Sciences Lund, Pediatrics, Lund University, Skane University Hospital, Lund, Sweden.ORCID 0000-0002-8302-7174
Michael M HawkinsCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-6496-4800
Raoul C ReulenCenter for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-7328-0467

Funding

Cancer Research UK 11709
6 · The paper itself

Abstract

backgroundSurvivors of Hodgkin lymphoma (HL) are at risk of developing non-Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide.

methodsThe Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow-Up Studies (PanCareSurFup) cohort includes 69,460 five-year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression.

resultsOverall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4-1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9-2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1-10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7-5.7), leukemia (SIR, 2.8; 95% CI, 1.8-4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4-5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2-3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7-2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8-1.5).

conclusionsIn addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.

Indexed as

Bone NeoplasmsHodgkin DiseaseKidney NeoplasmsLeukemiaLymphomaLymphoma, Non-HodgkinNeoplasms, Second PrimaryOsteosarcomaSarcomaWilms TumorAdolescentEuropeHumansIncidenceRisk FactorsSurvivorschildhood cancer survivorsHodgkin lymphomalate effectsnon-Hodgkin lymphomasecond cancerssubsequent primary lymphoma

Identifiers

PMID36444554
PMCPMC10099796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.